Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07283861 · ClinicalTrials.gov registry record · NA
Axoguard HA Plus Nerve Protector to Reduce Post-operative Neck and Shoulder Dysfunction in Patients Undergoing Neck Dissection
A NA study of Head and Neck Cancer and Neck Dissection, sponsored by Matthew Spector.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT07283861: Recruiting NA study of Head and Neck Cancer and Neck Dissection, sponsored by Matthew Spector.
NCT07283861 is a NA study of Head and Neck Cancer and Neck Dissection that is actively recruiting participants, run by Matthew Spector. The registered enrollment target is 90 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07283861, a NA study of Head and Neck Cancer and Neck Dissection, is actively recruiting participants, sponsored by Matthew Spector.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
In this prospective study, patients with head and neck cancers undergoing neck dissection will have the nerve to the shoulder wrapped with the Axoguard HA+ Nerve Protector at time of surgery. In these patients, the presence and severity of neck and shoulder dysfunction on the operated side will be assessed approximately twelve months post-operatively. The investigators hypothesize that shoulder nerve wrapping with the Axoguard HA+ Nerve Protector will lead to clinically meaningful improvement of shoulder function.
Primary Outcome
The neck dissection impairment index is a score from 1-100 with 100 being a perfect score.
Conditions Studied
Interventions
- DEVICE Spinal Accessory Nerve Protection utilizing Axoguard HA+
Study Locations (1)
Pennsylvania
- UPMC Presbyterian Shadyside - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2028-01 |
| Phase | NA |
What NCT07283861 shows while recruiting
NCT07283861 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Spinal Accessory Nerve Protection utilizing Axoguard HA+ is the first listed.
NCT07283861 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07283861 about?
NCT07283861 is a clinical study titled "Axoguard HA Plus Nerve Protector to Reduce Post-operative Neck and Shoulder Dysfunction in Patients Undergoing Neck Dissection". In this prospective study, patients with head and neck cancers undergoing neck dissection will have the nerve to the shoulder wrapped with the Axoguard HA+ Nerve Protector at time of surgery. In these patients, the presence and severity of neck and shoulder dysfunction on the operated side will be a...
What is the current status of trial NCT07283861?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2025-12-09. Estimated completion is 2028-01.
What conditions does trial NCT07283861 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Neck Dissection.
What interventions are being tested in trial NCT07283861?
The interventions under investigation include: Spinal Accessory Nerve Protection utilizing Axoguard HA+ (DEVICE).
Who is sponsoring clinical trial NCT07283861?
This trial is sponsored by Matthew Spector, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07283861 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07283861's enrollment target sits among peer trials
90 92nd of 250 higher than 158 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients
RECRUITING · NA
-
PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI